Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 12/20 | 0.53 |
| ▸ | HTR1B | P28222 | 10/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | HTR1F | P30939 | 2/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6801356 | 0.98 | HTR1D (0.51) | HTR1DHTR1BHTR1AHTR1FMTNR1A | |
| SCHEMBL7220850 | 0.85 | HTR1D (0.54) | HTR1DHTR1BHTR1AHTR1FCCR2 | |
| SCHEMBL6907469 | 0.85 | HTR1D (0.51) | HTR1DHTR1BHTR1AHTR1FCCR2 | |
| SCHEMBL6796075 | 0.85 | HTR1D (0.60) | HTR1DHTR1BHTR1AHTR1F | |
| SCHEMBL6794901 | 0.83 | MTNR1A (0.46) | HTR1DHTR1BHTR1AHTR1FMTNR1A | |
| SCHEMBL6795113 | 0.83 | MTNR1A (0.46) | HTR1DHTR1BHTR1AHTR1FMTNR1A | |
| SCHEMBL6795296 | 0.83 | MTNR1A (0.46) | HTR1DHTR1BHTR1AHTR1FMTNR1A | |
| SCHEMBL6795203 | 0.83 | MTNR1A (0.46) | HTR1DHTR1BHTR1AHTR1FMTNR1A | |
| SCHEMBL6796026 | 0.83 | HTR1D (0.48) | HTR1DHTR1AHTR1FMTNR1A | |
| SCHEMBL6796369 | 0.82 | OPRM1 (0.46) | HTR1DHTR1BCCR2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767907-B2 | FOR THERAPY OF PSYCHIC AND NEUROLOGIC DISORDERS | H. LUNDBECK A/S (DK) | 2004-07-27 | — | — | US | disclosed |
| US-6743808-B1 | PSYCHOLOGICAL AND NEUROLOGIC DISORDERS; CENTRAL SEROTONERGIC 5-HT1A AND 5-HT2A RECEPTOR ANTAGONISTS | H. LUNDBECK A/S (DK) | 2004-06-01 | — | — | US | disclosed |
| US-20030195356-A1 | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines | PERREGAARD JENS KRISTIAN (DK) | 2003-10-16 | — | — | US | disclosed |
| US-6218394-B1 | FOR THERAPY OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, SUCH AS GENERALISED ANXIETY DISORDER, PANIC DISORDER | H. LUNDBECK A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| EP-0765311-B1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | LUNDBECK & CO AS H (DK) | 2000-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195356-A1 | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines | CNR1, TPH1, CNR2 | HTR1D 4/4885HTR1B 32/4885HTR1A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.